In which countries and regions is Daprodustat available?

Since its clinical approval, daprodustat (Daprodustat) has been approved in many countries and regions and has become an effective treatment option for the treatment of anemia caused by chronic kidney disease (CKD). With its unique oral treatment form, this drug provides patients with a more convenient choice than traditional erythropoiesis stimulating agents (ESA), and its global marketing progress has also attracted much attention.

In Japan, daprostat was approved under the trade name Duvroq in 2020 in June for the treatment of anemia caused by chronic kidney disease. As the first oral therapeutic erythropoiesis-stimulating agent in the region, the launch of Duvroq has been widely welcomed by patients and doctors, especially among those who are unwilling to undergo injection therapy, and it provides a new treatment option.

In the United States, daprostat, under the trade name Jesduvroq, was fully approved by the FDA in February 2023, becoming the first oral treatment for anemia caused by chronic kidney disease in dialysis patients. Its approval marks a new breakthrough in the treatment of anemia in dialysis patients in the U.S. market, allowing patients to choose a more convenient oral medication to replace traditional injectable erythropoiesis stimulating agents. This approval has a profound impact on treatment patterns for dialysis patients, providing more flexible treatment options.

Although dapostat is approved in Japan and the United States and provides new treatment opportunities for patients with chronic kidney disease, its launch in other regions continues to evolve. In some countries and regions, daplestat may not yet be approved or may be undergoing clinical trials and approval processes. In the next few years, as global medical needs increase, dapinostat is expected to be approved in more countries and regions and become an important treatment option for the treatment of anemia worldwide.

Reference: https://en.wikipedia.org/wiki/Daprodustat